Michal Eisenbach-Schwartz,Kuti Baruch,Neta Rosenzweig
申请号：
US15261945
公开号：
US10519237B2
申请日:
2016.09.10
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
